Search results for "PPAR"

showing 10 items of 1686 documents

Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients

2018

Abstract Background The correct management of immunocompromised patients with pneumonia is debated. We evaluated the prevalence, risk factors, and characteristics of immunocompromised patients coming from the community with pneumonia. Methods We conducted a secondary analysis of an international, multicenter study enrolling adult patients coming from the community with pneumonia and hospitalized in 222 hospitals in 54 countries worldwide. Risk factors for immunocompromise included AIDS, aplastic anemia, asplenia, hematological cancer, chemotherapy, neutropenia, biological drug use, lung transplantation, chronic steroid use, and solid tumor. Results At least 1 risk factor for immunocompromis…

0301 basic medicineMalePediatricsEtiologyMultidrug-resistant pathogenMRSAPneumocystis pneumoniaPneumònia adquirida a la comunitatHOSPITALIZED-PATIENTS0302 clinical medicineCommunity-acquired pneumoniaRisk FactorsPrevalenceMedicine030212 general & internal medicinePNEUMOCYSTIS PNEUMONIAArticles and CommentariesAged 80 and overRespiratory tract infectionsAnemia AplasticMiddle Aged3. Good healthCommunity-Acquired InfectionsEuropeInfectious DiseasesImmunocompromise; Microbiology; MRSA; Multidrug-resistant pathogens; PneumoniaEtiologiaHematologic NeoplasmsFemaleBLOOD-STREAM INFECTIONSLung TransplantationMicrobiology (medical)medicine.medical_specialtyAsiaNeutropeniaCommunity-acquired pneumonia030106 microbiologyRESPIRATORY-TRACT INFECTIONSHematologic NeoplasmsSettore MED/10 - Malattie Dell'Apparato RespiratorioTRANSPLANT RECIPIENTSDISEASES-SOCIETYMicrobiology03 medical and health sciencesImmunocompromised HostPneumonia BacterialMANAGEMENTHumanspneumoniaBACTERIAL PNEUMONIAImmunocompromiseAgedAcquired Immunodeficiency Syndromebusiness.industrymicrobiologyBacterial pneumoniaAustraliaPneumoniamedicine.diseaseMultidrug-resistant pathogensPneumoniamultidrug-resistant pathogensMycosesBacteremiaAfricaEtiologyRISK-FACTORSimmunocompromiseAmericasbusinessClinical Infectious Diseases
researchProduct

International prevalence and risk factors evaluation for drug-resistant Streptococcus pneumoniae pneumonia

2019

Objective: Streptococcus pneumoniae is the most frequent bacterial pathogen isolated in subjects with Community-acquired pneumonia (CAP) worldwide. Limited data are available regarding the current global burden and risk factors associated with drug-resistant Streptococcus pneumoniae (DRSP) in CAP subjects. We assessed the multinational prevalence and risk factors for DRSP-CAP in a multinational point-prevalence study. Design: The prevalence of DRSP-CAP was assessed by identification of DRSP in blood or respiratory samples among adults hospitalized with CAP in 54 countries. Prevalence and risk factors were compared among subjects that had microbiological testing and antibiotic susceptibility…

0301 basic medicineMaleStreptococcus pneumoniaantibiotic resistanceInternationalitysputum examinationbronchiectasisvery elderlyAntibioticsPrevalenceDrug resistancemedicine.disease_causeLogistic regressionGlobal HealthCommunity-Acquired Infections/epidemiologylung lavage0302 clinical medicineCommunity-acquired pneumoniaCost of IllnessRisk FactorsPrevalencedrug resistant Streptococcus pneumoniae pneumonia030212 general & internal medicineMicrobial drug resistantAged 80 and overadultinternational cooperationdrug effectMiddle Agedinfluenza vaccinationAnti-Bacterial Agentsantiinfective agentEuropeCommunity-Acquired InfectionsHospitalizationGlobal burden of diseaseStreptococcus pneumoniaeInfectious Diseasesrisk factorbacterium identificationFemalecommunity acquired infectioninfluenzaliver diseasepneumococcal vaccinationPneumococcal infectionhospitalizationmedicine.drugMicrobiology (medical)medicine.medical_specialtyAsiamedicine.drug_class030106 microbiologySettore MED/10 - Malattie Dell'Apparato RespiratorioArticleAnti-Bacterial Agents/pharmacology03 medical and health sciencesInternal medicineStreptococcus pneumoniaeDrug Resistance BacterialPneumonia Pneumococcal/epidemiologymedicineHumanscontrolled studyhumantetracyclineHospitalization/statistics & numerical dataAgedlevofloxacinnonhumanbusiness.industrydisease associationmicrobiologycommunity acquired pneumoniamacrolidePneumoniaasthmaSouth AmericaPneumonia Pneumococcalvaccinationmedicine.diseasemajor clinical studyantibiotic sensitivitypenicillin derivativePenicillinStreptococcus pneumoniae/drug effectsPneumoniablood examinationAfricaNorth Americamicrobiological examinationbusinessGlobal burden of disease; Microbial drug resistant; Pneumococcal infection; Pneumonia
researchProduct

Skeletal muscle Heat shock protein 60 increases after endurance training and induces peroxisome proliferator-activated receptor gamma coactivator 1 α…

2016

AbstractHeat shock protein 60 (Hsp60) is a chaperone localizing in skeletal muscle mitochondria, whose role is poorly understood. In the present study, the levels of Hsp60 in fibres of the entire posterior group of hindlimb muscles (gastrocnemius, soleus and plantaris) were evaluated in mice after completing a 6-week endurance training program. The correlation between Hsp60 levels and the expression of four isoforms of peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC1α) were investigated only in soleus. Short-term overexpression of hsp60, achieved by in vitro plasmid transfection, was then performed to determine whether this chaperone could have a role in the activa…

0301 basic medicineMaleTime FactorsPPARgammaPeroxisome proliferator-activated receptorExosomesMiceendurance trainingMyocytechemistry.chemical_classificationMultidisciplinarytrainingbiologyHsp60Mitochondriamedicine.anatomical_structureMuscle Fibers Slow-TwitchMuscle Fibers Fast-TwitchHsp60; skeletal muscle; training; PPARgamma; PGC1αHSP60[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]Oxidation-Reductionmedicine.medical_specialtyanimal structureschemical and pharmacologic phenomenacomplex mixturescachexiaArticleCell Line03 medical and health sciencesEndurance trainingHeat shock proteinInternal medicinePhysical Conditioning AnimalPGC1αCoactivatormedicineAnimals[SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]skeletal muscleMuscle SkeletalSettore BIO/16 - Anatomia UmanafungiSkeletal muscleChaperonin 60030104 developmental biologyEndocrinologychemistryGene Expression RegulationChaperone (protein)biology.proteinPhysical EnduranceBiomarkersTranscription FactorsScientific Reports
researchProduct

When Three Isn't a Crowd: A Digyny Concept for Treatment-Resistant, Near-Triploid Human Cancers.

2019

Near-triploid human tumors are frequently resistant to radio/chemotherapy through mechanisms that are unclear. We recently reported a tight association of male tumor triploidy with XXY karyotypes based on a meta-analysis of 15 tumor cohorts extracted from the Mitelman database. Here we provide a conceptual framework of the digyny-like origin of this karyotype based on the germline features of malignant tumors and adaptive capacity of digyny, which supports survival in adverse conditions. Studying how the recombinatorial reproduction via diploidy can be executed in primary cancer samples and HeLa cells after DNA damage, we report the first evidence that diploid and triploid cell sub-populati…

0301 basic medicineMalelcsh:QH426-470DNA repairKaryotypeSpindle ApparatusDigynyBiologyGenomeGermline03 medical and health sciencesnear-triploid cancer0302 clinical medicineMeiosisNeoplasmsGeneticsTumor Cells Culturedtumor blastomeresHumansGeneGenetics (clinical)GeneticsChromosomes Human XChromosomes Human YModels Geneticfungifood and beverageschemoresistancereprogrammingKaryotypeConcept Papertripolar mitosisTriploidyradioresistancelcsh:GeneticsMeiosis030104 developmental biologyGerm Cellspedogamy030220 oncology & carcinogenesisNeoplastic Stem Cellspolynuclear cancer cellsPloidyHeLa CellsdigynyGenes
researchProduct

Nonacidic Farnesoid X Receptor Modulators.

2017

As a cellular bile acid sensor, farnesoid X receptor (FXR) participates in regulation of bile acid, lipid and glucose homeostasis, and liver protection. Clinical results have validated FXR as therapeutic target in hepatic and metabolic diseases. To date, potent FXR agonists share a negatively ionizable function that might compromise their pharmacokinetic distribution and behavior. Here we report the development and characterization of a high-affinity FXR modulator not comprising an acidic residue.

0301 basic medicineMalemedicine.drug_classPyridinesPeroxisome proliferator-activated receptorReceptors Cytoplasmic and NuclearATP-binding cassette transporterCholesterol 7 alpha-hydroxylase01 natural sciencesRats Sprague-Dawley03 medical and health sciencesStructure-Activity RelationshipDrug StabilityDrug DiscoverymedicineGlucose homeostasisAnimalsHumansPPAR alphaReceptorCholesterol 7-alpha-HydroxylaseATP Binding Cassette Transporter Subfamily B Member 11chemistry.chemical_classificationBile acid010405 organic chemistryChemistryHEK 293 cellsImidazolesMembrane Transport ProteinsHep G2 Cells0104 chemical sciencesMolecular Docking SimulationZolpidem030104 developmental biologyHEK293 CellsBiochemistryMolecular MedicineFarnesoid X receptorATP-Binding Cassette TransportersSterol Regulatory Element Binding Protein 1HeLa CellsJournal of medicinal chemistry
researchProduct

Bioactive triterpenes of protium heptaphyllum gum resin extract display cholesterol-lowering potential

2021

Hypercholesterolemia is one of the major causes of cardiovascular disease, the risk of which is further increased if other forms of dyslipidemia occur. Current therapeutic strategies include changes in lifestyle coupled with drug administration. Statins represent the most common therapeutic approach, but they may be insufficient due to the onset of resistance mechanisms and side effects. Consequently, patients with mild hypercholesterolemia prefer the use of food supplements since these are perceived to be safer. Here, we investigate the phytochemical profile and cholesterol-lowering potential of Protium heptaphyllum gum resin extract (PHE). Chemical characterization via HPLC-APCI-HRMS2 and…

0301 basic medicineModels MolecularProtein ConformationDrug Evaluation Preclinical030204 cardiovascular system & hematologyPharmacologyPPARαTerpenelcsh:ChemistryPCSK9chemistry.chemical_compound0302 clinical medicineCatalytic DomainSettore BIO/10 - BiochimicaPlant Gumslcsh:QH301-705.5SpectroscopyChromatography High Pressure LiquidFlame IonizationMonacolinChemistryAnticholesteremic AgentsGeneral MedicineComputer Science ApplicationsMolecular Docking SimulationCholesterolPhytochemicalMolecular dockinglipids (amino acids peptides and proteins)Breu brancoStatinmedicine.drug_classHypercholesterolemiaArticleCatalysisGas Chromatography-Mass SpectrometryInorganic Chemistry03 medical and health sciencesNutraceuticalmedicineHumansLovastatinPhysical and Theoretical ChemistryMolecular BiologyOleananeHMGCREnzymatic activityCholesterolPCSK9Organic ChemistryStatinSettore CHIM/08 - Chimica FarmaceuticaTriterpenes030104 developmental biologyhypercholesterolemia; gene expression; HMGCR; PCSK9; PPARα; enzymatic activity; molecular docking; statin; monacolin; breu brancolcsh:Biology (General)lcsh:QD1-999Breu branco; Enzymatic activity; Gene expression; HMGCR; Hypercholesterolemia; Molecular docking; Monacolin; PCSK9; PPARα; StatinLDL receptorDietary SupplementsHepatocytesSettore BIO/14 - FarmacologiaGene expressionHydroxymethylglutaryl-CoA Reductase InhibitorsResins PlantHydrogen
researchProduct

Cardiovascular Issues in Tyrosine Kinase Inhibitors Treatments for Chronic Myeloid Leukemia: A Review

2021

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm driven by a fusion gene, encoding for the chimeric protein BCR-ABL, with constitutive tyrosine kinase activity. The use of tyrosine kinase inhibitors (TKIs) has drastically improved survival, but there are significant concerns about cardiovascular toxicity. Cardiovascular risk can be lowered with appropriate baseline evaluation, accurate choice of TKI therapy, improvement of modifiable cardiovascular risk factors through lifestyle modifications, and prescription of drugs for primary or secondary prevention. Which examinations are necessary, and when do they have to be scheduled? How often should a TKI-treated patient undergo wh…

0301 basic medicineOncologycardiovascular riskmedicine.medical_specialtychronic myelocytic leukemiacardio-oncologyPhysiologyReviewSettore MED/15 - Malattie Del Sangue03 medical and health sciencescardiovascular events0302 clinical medicineInternal medicinePhysiology (medical)hemic and lymphatic diseasesmedicineNeoplasmQP1-981Medical prescriptionAdverse effectMyeloproliferative neoplasmHematologyMechanism (biology)business.industryMyeloid leukemiamedicine.diseaseSettore MED/11 - Malattie Dell'Apparato Cardiovascolarerespiratory tract diseasestyrosine kinase inhibitions therapy030104 developmental biology030220 oncology & carcinogenesiscardiovascular events chronic myelocytic leukemia cardiovascular risk cardio-oncology tyrosine kinase inhibitions therapybusinessTyrosine kinaseFrontiers in Physiology
researchProduct

Anticancer properties of 4-thiazolidinone derivatives depend on peroxisome proliferator-activated receptor gamma (PPARγ)

2017

Peroxisome proliferator-activated receptors (PPARs) play an important role in numerous chronic diseases such as diabetes, obesity, atherosclerosis and cancer, and PPAR modulators are among the approved drugs and drug-candidates for their treatment. The aim of this study was to elucidate the involvement of PPARs in the mechanism of cytotoxic and pro-apoptotic action of novel anticancer 4-thiazolidinone derivatives (Les-2194, Les-3377, Les-3640) and approved 4-thiazolidinones (Rosiglitazone, Pioglitazone) towards the human squamous carcinoma (SCC-15) cell line. Experiments with 4-thiazaolidinone derivatives and PPAR-specific siRNA were conducted and PPARα, PPARβ and PPARγ mRNA expression was …

0301 basic medicinePPARsCytotoxicityPeroxisome proliferator-activated receptorAntineoplastic AgentsApoptosisPharmacologySCC-1503 medical and health sciencesStructure-Activity Relationship0302 clinical medicineCell Line TumorDrug DiscoverymedicineGene silencingHumansViability assayRNA MessengerReceptorCell ProliferationPharmacologychemistry.chemical_classificationGene knockdownDose-Response Relationship DrugMolecular StructureThiazolothiopyranesOrganic ChemistryGeneral MedicineSquamous carcinomaPPAR gamma030104 developmental biologychemistryCell cultureThiazolidinone030220 oncology & carcinogenesisThiazolidinesDrug Screening Assays AntitumorRosiglitazonemedicine.drugEuropean Journal of Medicinal Chemistry
researchProduct

PPAR Agonists, Atherogenic Dyslipidemia and Cardiovascular Risk.

2016

Peroxisome proliferator-activated receptors (PPAR) are implicated in the pathology of several metabolic diseases including obesity, diabetes, and atherosclerosis. PPAR agonists exert multiple lipid modifying actions which are beneficial to the prevention of atherosclerosis. Such benefits in lipid lowering actions include improvements in atherogenic dyslipidemia that seems to be particularly expressed in individuals at higher cardiovascular (CV) risk. In addition, the favorable effects of PPAR agonists on different cardio-metabolic parameters are established in several metabolic conditions, such as diabetes mellitus, insulin resistance, and heightened systemic inflammation. The goal of this …

0301 basic medicinePeroxisome Proliferator-Activated Receptormedicine.medical_specialtyPeroxisome Proliferator-Activated ReceptorsPeroxisome proliferator-activated receptor030204 cardiovascular system & hematologyBioinformaticsSystemic inflammationPPAR agonist03 medical and health sciences0302 clinical medicineInsulin resistanceRisk FactorsCardiovascular DiseaseInternal medicineDiabetes mellitusDrug DiscoverymedicineAnimalsHumansDyslipidemiasHypolipidemic AgentsPharmacologychemistry.chemical_classificationClinical Trials as TopicHypolipidemic Agentmedicine.diagnostic_testAnimalbusiness.industryRisk FactorAtherogenic dyslipidemiaCardiovascular riskmedicine.diseaseAtherosclerosisObesityThiazoles030104 developmental biologyEndocrinologyDyslipidemiachemistryCardiovascular DiseasesAtherosclerosilipids (amino acids peptides and proteins)medicine.symptomLipid profilebusinessHumanLipoproteinCurrent pharmaceutical design
researchProduct

Impact of elastin-derived VGVAPG peptide on bidirectional interaction between peroxisome proliferator-activated receptor gamma (Pparγ) and beta-galac…

2018

The process of degradation of the elastin-rich extracellular matrix produces elastin-derived peptides (EDPs). Different types of EDPs are detectable in the cerebrospinal fluid in healthy individuals and in patients after ischemic stroke. To date, it has been demonstrated that EDPs can regulate the development of insulin resistance in mice in a peroxisome proliferator-activated receptor gamma (Pparγ)-dependent manner. Therefore, the aim of this study was to investigate the impact of the elastin-derived valine-glycine-valine-alanine-proline-glycine (VGVAPG) peptide on Pparγ and beta-galactosidase (β-Gal) expression in mouse cortical astrocytes in vitro. Primary astrocytes were maintained in D…

0301 basic medicinePeroxisome proliferator-activated receptorPeptideEDPPparγ03 medical and health sciencesMice0302 clinical medicinemedicineAnimalsRNA MessengerRNA Small InterferingReceptorCells CulturedPharmacologychemistry.chemical_classificationMessenger RNAGene knockdownGeneral Medicinebeta-GalactosidaseIn vitroCell biologyElastinElastin-derived peptidesPPAR gamma030104 developmental biologymedicine.anatomical_structurechemistryVGVAPGAstrocytesβ-GalFemaleAstrocyteOligopeptides030217 neurology & neurosurgeryFetal bovine serumAstrocyteNaunyn-Schmiedebergs Archives of Pharmacology
researchProduct